Status:
COMPLETED
Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention
Lead Sponsor:
Benha University
Conditions:
Ovarian Hyperstimulation
Eligibility:
FEMALE
18-45 years
Phase:
PHASE3
Brief Summary
Giving oral Cabergoline or calcium infusion in women at high risk for developing ovarian hyperstimulation syndrome in context of assisted reproductive technologies aiming in its prevention
Detailed Description
Women undergoing in vitro fertilization or intracytoplasmic sperm injection whom were at high risk for developing ovarian hyperstimuation syndrome were received either oral Cabergoline.5mg tablets for...
Eligibility Criteria
Inclusion
- women undergoing assisted reproductive technologies whom at high risk for developing ovarian hyperstimulation syndrome as with high basal antimullerian hormone ,excess antral follicular count ,high seum estradiol on day of humian choronic gonadotrophin
Exclusion
- women with other endocrinopathy as congenital adrenal hyperplasia , hyperprolactinemia,diabetes
- \-
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 15 2017
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT03473613
Start Date
October 1 2014
End Date
April 15 2017
Last Update
March 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ashraf nassif Elmantwe
Cairo, Elqalopia, Egypt, 5131